
The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.






















































































































































































































